PubMed
Cerebrolysin for acute ischemic stroke (review)
Chen et al., 2017
Neurological & CognitiveIntl. ApprovedB
Cerebrolysin
FPE 1070
Cerebrolysin (FPE 1070) is a porcine brain-derived neuropeptide preparation containing a mixture of neurotrophic peptide fractions including BDNF-, NGF-, CNTF-, and GDNF-like fragments (<10kDa). Approved in Austria, Russia, China, South Korea, and other countries for Alzheimer's disease, post-stroke recovery, and traumatic brain injury. Multiple randomized controlled trials have demonstrated cognitive and functional improvements. Not FDA-approved in the US.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 5
- Research grade
- B
- Experience
- 100
- Activity
- 53
Overall check-ins
Trackers & reports
Overview
About Cerebrolysin
Cerebrolysin (FPE 1070) is a porcine brain-derived neuropeptide preparation containing a mixture of neurotrophic peptide fractions including BDNF-, NGF-, CNTF-, and GDNF-like fragments (<10kDa). Approved in Austria, Russia, China, South Korea, and other countries for Alzheimer's disease, post-stroke recovery, and traumatic brain injury. Multiple randomized controlled trials have demonstrated cognitive and functional improvements. Not FDA-approved in the US.
- Category
- Neurological & Cognitive
- Regulatory status
- Intl. Approved
- Also known as
- FPE 1070
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Cognition
6
Self-reported dose per injection
Median bucket: 0–25 mcg · Most common: 0–25 mcg
Reports span 0–50 mcg
0–25
4
25–50
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Research
Cited research (3)
Source
PubMed
Cerebrolysin for acute ischaemic stroke
Ziganshina et al., 2023
PubMed
Cerebrolysin for acute ischaemic stroke
Ziganshina et al., 2017
Tools
Explore more
Explore
More ways to learn about Cerebrolysin from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Cerebrolysin?
This page summarizes 6 anonymized self-reports from PeptIQ users who track Cerebrolysin, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Cerebrolysin?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Cerebrolysin?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Cerebrolysin safe to use?
This wiki does not assess safety or recommend use. Cerebrolysin is listed as Intl. Approved. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Cerebrolysin?
This wiki summarizes observational community reports and linked citations for Cerebrolysin. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for Cerebrolysin for study-level context — not medical advice.
What is the legal status of Cerebrolysin?
Cerebrolysin is listed in PeptIQ as Intl. Approved. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of Cerebrolysin?
Safety data quality for Cerebrolysin varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on Cerebrolysin?
This page links 3 indexed sources for Cerebrolysin. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.